Keyphrases
Retrospective Analysis
100%
Clear Cell Renal Cell Carcinoma (ccRCC)
100%
Cabozantinib
100%
Confidence Interval
37%
Disease Progression
25%
Dose Reduction
25%
Overall Survival
25%
Progression-free Survival
25%
Partial Response
25%
Stable Disease
25%
Vascular Endothelial Growth Factor
12%
Progressive Disease
12%
Clinically Significant
12%
Clinical Data
12%
Median Overall Survival
12%
Baseline Characteristics
12%
Kinase Inhibitor
12%
History Data
12%
Objective Response Rate
12%
Metastatic Renal Cell Carcinoma (mRCC)
12%
Papillary
12%
Patient History
12%
Papillary Renal Cell Carcinoma (pRCC)
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Radiological Response
12%
Median Progression-free Survival
12%
January 2017
12%
VEGFR-TKI
12%
Chromophobe
12%
Abdominal Radiologist
12%
Disease Control Rate
12%
Savolitinib
12%
Unclassified Renal Cell Carcinoma
12%
Measurable Disease
12%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Cabozantinib
100%
Disease
50%
Overall Survival
37%
Progression Free Survival
37%
Retrospective Study
25%
Disease Exacerbation
25%
Drug Dose Reduction
25%
Vasculotropin
12%
Progressive Disease
12%
Phosphotransferase Inhibitor
12%
Papillary Renal Cell Carcinomas
12%
Savolitinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Cabozantinib
100%
Disease
62%
Overall Survival
37%
Progression Free Survival
37%
Retrospective Study
25%
Disease Exacerbation
25%
Vasculotropin
12%
Medical History
12%
Phosphotransferase Inhibitor
12%
Dose Toxicity
12%
Savolitinib
12%